Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	70.04	54.53	142.82	144.42	229.79
Short-Term Investments	-	46.62	-	29.88	-
Cash & Short-Term Investments	70.04	101.15	142.82	174.3	229.79
Cash Growth	-30.76%	-29.18%	-18.06%	-24.15%	195.14%
Other Current Assets	1.74	2.92	4.99	6.72	2.96
Total Current Assets	71.78	104.07	147.81	181.02	232.75
Net Property, Plant & Equipment	0.28	0.27	0.52	0.27	0.38
Other Long-Term Assets	-	0.27	-	-	-
Total Assets	72.06	104.61	148.33	181.29	233.14
Accounts Payable	0.16	0.18	1.34	0.13	1.02
Accrued Expenses	6.12	12.12	5.54	14.07	10.52
Current Portion of Long-Term Debt	15.25	0.03	15.15	0.91	-
Current Portion of Leases	0.28	0.27	0.24	0.25	0.23
Unearned Revenue	6	6	-	-	-
Total Current Liabilities	27.81	18.6	22.26	15.36	11.77
Long-Term Debt	-	15	-	14.92	15.5
Long-Term Leases	-	-	0.27	-	0.13
Other Long-Term Liabilities	-	-	6	-	-
Total Long-Term Liabilities	-	15	6.27	14.92	15.63
Total Liabilities	27.81	33.6	28.53	30.28	27.4
Common Stock	0.06	0.06	0.06	0.06	0.06
Additional Paid-in Capital	528.15	521.02	513.99	507.77	500.37
Accumulated Other Comprehensive Income	-	0.04	-	-0.1	-
Retained Earnings	-483.96	-450.11	-394.26	-356.72	-294.69
Shareholders' Equity	44.25	71	119.8	151.01	205.74
Total Liabilities & Equity	72.06	104.61	148.33	181.29	233.14
Total Debt	15.53	15.3	15.66	16.08	15.86
Net Cash (Debt)	54.51	85.85	127.17	158.22	213.93
Net Cash Growth	-36.50%	-32.49%	-19.63%	-26.04%	242.12%
Net Cash Per Share	0.91	1.44	2.16	2.71	3.96
Book Value	44.25	71	119.8	151.01	205.74
Book Value Per Share	0.74	1.19	2.03	2.59	3.81
Tangible Book Value	44.25	71	119.8	151.01	205.74
Tangible Book Value Per Share	0.74	1.19	2.03	2.59	3.81

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q